actemra 162 mg/0.9 ml rastvor za injekciju u napunjenoj šprici
roche d.o.o.roche ltd. - tocilizumab - rastvor za injekciju u napunjenoj šprici - 162 mg/0.9 ml - 0,9 ml rastvora za injekciju sadrži: 162 mg tocilizumab
hemlibra (▼) 30 mg/1 ml otopina za injekciju
roche d.o.o.roche ltd. - emicizumab - otopina za injekciju - 30 mg/1 ml - 1 bočica sa 1 ml otopine za injekciju sadrži: 30 mg emicizumaba
hemlibra (▼) 60 mg/0.4 ml otopina za injekciju
roche d.o.o.roche ltd. - emicizumab - otopina za injekciju - 60 mg/0.4 ml - 1 bočica sa 0,4 ml otopine za injekciju sadrži: 60 mg emicizumaba
hemlibra (▼) 105 mg/0.7 ml otopina za injekciju
roche d.o.o.roche ltd. - emicizumab - otopina za injekciju - 105 mg/0.7 ml - 1 bočica sa 0,7 ml otopine za injekciju sadrži: 105 mg emicizumaba
hemlibra (▼) 150 mg/1 ml otopina za injekciju
roche d.o.o.roche ltd. - emicizumab - otopina za injekciju - 150 mg/1 ml - 1 bočica sa 1 ml otopine za injekciju sadrži: 150 mg emicizumaba
bretaris genuair (▼) 322 µg/1 doza prašak za inhaliranje
berlin chemie / menarini bh d.o.o. sarajevo - aklidinijum - prašak za inhaliranje - 322 µg/1 doza - 1 doza praška za inhaliranje sadrži: 322 mcg aklidinijuma (što odgovara 375 mcg aklidinujum bromida)
bretaris genuair (▼) 322 µg/1 doza prašak za inhaliranje
berlin chemie / menarini bh d.o.o. sarajevo - aklidinijum - prašak za inhaliranje - 322 µg/1 doza - 1 doza praška za inhaliranje sadrži: 322 mcg aklidinijuma (što odgovara 375 mcg aklidinujum bromida)
bretaris genuair (▼) 322 µg/1 doza prašak za inhaliranje
berlin chemie / menarini bh d.o.o. sarajevo - aklidinijum - prašak za inhaliranje - 322 µg/1 doza - 1 doza praška za inhaliranje sadrži: 322 mcg aklidinijuma (što odgovara 375 mcg aklidinujum bromida)
leqvio
novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - sredstva za modifikaciju lipida - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
ronapreve
roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - imuni serumi i homologna, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. pogledajte odjeljke 4. 4 i 5.